|
FY2013
12 months to Dec 31, 2013
|
FY2012
12 months to Dec 31, 2012
|
|
|---|---|---|
| Revenues | ||
| Pharmaceutical net sales | ||
| Contract manufacturing net sales | ||
| Total net sales | ||
| Cost of sales (exclusive of amortization of purchased technology and IPR&D asset) | ||
| Gross profit | ||
| Operating expenses: | ||
| Selling and marketing | ||
| General and administrative | ||
| Research and development | ||
| Depreciation and amortization | ||
| Change in fair value of contingent consideration | ||
| Impairment of goodwill and intangibles | ||
| Impairment of goodwill | ||
| Total operating expenses | ||
| Income from operations | ||
| Interest and other (expense) income, net | ||
| Total other income | ||
| Foreign currency transaction loss | ||
| Income before income taxes | ||
| Income tax expense | ||
| Net income | ||
| Available-for-sale Securities, Change in Net Unrealized Holding Gain (Loss), Net of Tax | ||
| Change in unrealized gains or losses on available-for-sale securities, net of related tax effects. | ||
| Change foreign currency translation adjustments. | ||
| Comprehensive Income | ||
| Net income per share applicable to common shareholders: | ||
| Basic (in dollars per share) | ||
| Diluted (in dollars per share) | ||
| Shares used in computing net income per share applicable to common shareholders: | ||
| Basic (in shares) | ||
| Diluted (in shares) | ||
| Dividends declared per common share |
Loading...
